PRIME Journal Vol. 11 Issue 3

NEWS | 10 June/July 2021 | REALSELFACQUIRESYNSGROUP EXPANDINGCONSUMERREACH ACQUISITIONADDSMORE THANTHREEMILLIONMONTHLY ACTIVE USERS, the medical aesthetics industry’s leading community and marketplace, announced the acquisition of YNS Group, a portfolio of online destinations - including ,, and .—serving millions of international consumers throughout Europe and LATAM. Similar to RealSelf, the YNS platforms provide aesthetics consumers invaluable services including doctor reviews and online booking, patient testimonials, procedure information, and access to their community who offer helpful advice and guidance. Acquisitions ‘Following our January 2021 acquisition of—the leading cosmetic procedure resource for Arabic speaking consumers—this addition establishes RealSelf properties as the global go-to destinations for all things modern beauty while expanding our market coverage into new geographies,’ said RealSelf CEO, James Coyle. ‘From skincare, to minimally invasive, to surgical procedures, and whether you’re in Seattle or Spain, RealSelf together with YNS are here to help consumers with each step of their modern beauty journey.’ Attracting consumers Consumers have experienced a massive shift in lifestyle due to the pandemic including virtual, work-from-home arrangements which have allowed for more discreet, at-home procedure recoveries. These factors have contributed to continued interest in the $17 billion dollar global medical aesthetics industry and RealSelf believes it is primed and poised to meet consumers’ worldwide demand with this acquisition. ‘RealSelf and YNS are the perfect match to build upon and deliver global momentum in the aesthetics market. We are bringing together two remarkable customer-centric teams passionate about continually improving how consumers, doctors, and brands interact and are ecstatic to join forces to accelerate growth,’ said YNS Group CEO, José Luis Ferrer. ‘Combining our respective in-market expertise with a track record of driving innovation, together we are confident we can make even more of a positive impact on how consumers research cosmetic treatments, share their experiences, and connect with top providers.’ The future ‘At RealSelf we are relentless about providing trusted, high-quality, unbiased medical aesthetics information so that every investment in modern beauty is worth it,’ said Coyle. ‘With this acquisition, we’re expanding our vision further across the globe and together, we’re making the experience easier for millions of more consumers to make smart, confident decisions through even more patient reviews, unretouched before & after photos, access to medical experts, and in-depth procedure information. We’re excited to innovate even further and drive growth.’ Advanced Aesthetic Technologies, Inc., a leader in aesthetic gel implant technology, announced that Algeness® VL (2.5% agarose gel) demonstrated equivalent efficacy, safety, and usability compared to those of NASHA-L based on a split-face study published in the Journal of Cosmetic Dermatology . ‘Agarose gel filler is a naturally occurring polymer gel with a three- dimensional structure similar to the extracellular matrix, which achieves its duration without the need for crosslinking. Our objective with this study of 66 patients was to determine the efficacy and safety of 2.5% agarose gel filler for the correction of nasolabial folds as compared with NASHA-L. Our assessments included assessment of the nasolabial fold (NLF), Wrinkle Severity Rating Scale (WSRS), Global Aesthetic Improvement Scale (GAIS [blinded investigator]), as well as subject satisfaction, adverse events, and usability,’ according to lead investigator Nicolò Scuderi, MD, of the Department of General and Plastic Surgery at the University of La Sapienza, Rome, Italy. Among the 66 participants in the study, 46 individuals or 66.7% were available for evaluation at 3 months, when mean change in WSRS was identical for both products (−1.1 ± 0.4 for 2.5% agarose; −1.1 ± 0.4 for NASHA-L). Scores for each product remained similar across all time points and began to return to baseline between 7 and 8 months. GAIS score followed a similar pattern, rising between months 7 and 8 (2.7 ± 0.6 for 2.5% agarose at month 7 and 3.3 ± 0.5 at month 8, vs. 2.7 ± 0.6 for NASHA-L at month 7-3.3 ± 0.5 at month 8). All adverse events were transient in nature and resolved within 15 days, most events were mild in nature, and the number and severity of events was similar between the two fillers. According to Dr. Scuderi, ‘We continue to be impressed with the clinical outcomes of the novel Algeness® range of dermal fillers. This is the first 100% natural, biocompatible and biodegradable filler on the market to date, which differentiates it from other injectable products.’ RealSelf properties will now servemore than 100Mconsumers annually acrossmore than 170 countries. POSITIVESTUDY RESULTSFOR ALGENESS®VL R